With the U.S. Food and Drug Administration’s approval for phase two trials, researchers are hoping that the Israeli drug Aviptadil, will be able to eliminate the so-called Acute Respiratory Distress Syndrome (ARDS), the condition responsible for the deaths of about 50% of all COVID-19 patients.
By i24NEWS
The U.S. Food and Drug Administration on Sunday has cleared NeuroRx, a US-Israeli pharmaceutical company, and Relief Therapeutics, a Swiss drug development company, for phase two trials for a drug that could take on a deadly condition associated with COVID-19.
The two companies announced that the FDA issued a “study may proceed” letter — which does not amount to a full-fledged drug approval — for the substance to be tried on COVID-19 patients. Continue Reading »
Israeli New Shekel Exchange Rate